Taurine and Metabolic Disorders: From Mechanisms to Clinical Implications.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and clinical studies without a systematic search or meta-analysis.
PubMed 42313687 · doi:10.1159/000552198
What was done
This review summarized literature on the biological mechanisms of taurine and its role in metabolic disorders such as obesity, type 2 diabetes, metabolic dysfunction-associated liver disease, and metabolic syndrome. The authors evaluated proposed cellular pathways (including AMPK, PPAR-alpha, NF-kappa B, and mitochondrial support) alongside preclinical models and human clinical trials.
What was found
No numerical results or effect sizes were reported in the abstract. Preclinical models demonstrated improvements in insulin sensitivity and inflammatory profiles with taurine administration. Human trials suggested potential benefits in glycemic control and lipid metabolism, though findings were limited by inconsistent dosing, treatment duration, and subject stratification.
Why it matters
The paper outlines how taurine regulates energy metabolism, inflammation, and insulin sensitivity. This provides a theoretical framework for future clinical research investigating taurine supplementation for metabolic conditions.
Limits
The review relies on preclinical data and small, heterogeneous human trials with variable dosages and treatment durations. No original quantitative data, systematic review methodology, or meta-analytic pooling were presented in the abstract.
Cited by
- supports Taurine plays a functional role in cellular mitochondrial function and energy production.